Phase 1b Multicenter Open-label Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors

Brief description of study

This study is testing two drugs called RMC-6291 and RMC-6236 in patients with advanced KRASG12C-mutated solid tumors. The study team is trying to figure out the right amount of each drug to give and how often to give it that has few side effects and is effective in treatment. The study has two parts: one where they start with a small dose and gradually increase it to see how patients react, and another where they use the best dose they found in the first part with few side effects to see if it works well. The study team will be very careful to make sure people stay safe throughout the study. They'll start with just a few patients and then decide if they can include more based on how things are going.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.